<b><span style="font-family:Verdana;">Background: </span></b><span style="font-family:""><span style="font-family:Verdana;">The liver function tes...<b><span style="font-family:Verdana;">Background: </span></b><span style="font-family:""><span style="font-family:Verdana;">The liver function tests (LFTs) remain one of the most commonly employed clinical measures for the diagnosis of hepatobiliary disease. LFTs sometimes referred to as hepatic panel help to determine the health of liver, monitor the progression of a disease and measure the severity of a disease particularly scarring or cirrhosis of the liver. </span><b><span style="font-family:Verdana;">Aims: </span></b><span style="font-family:Verdana;">In this study, we present a new approach to evaluate the natural progression of liver disease through the assessment of eight biochemical </span><span style="font-family:Verdana;">parameters: serum total bilirubin (TB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Alkaline phosphatase (ALP), total protein (TP), albumin (ALB), albumin/globulin (A/G) ratio, and alpha-fetoprotein (AFP) as well as two ma</span><span style="font-family:Verdana;">chine learning (ML) tools—Random Forest and CART to substantive the outcome. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">The study was carried out in a total of 100 subjects which included healthy controls (group I-25 patients), patients with acute hepatitis (group II-25 patients), chronic hepatitis (group III-25 patients) and hepatocellular carcinoma (group IV-25 patients) applying both biochemical and Machine Learning methods. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Of the eight parameters tested, all except ALP (p = 0.426), showed an overall discriminatory ability as judged by one-factor analysis of variance (p < 0.0001). We also assessed the differences among group means by least significance difference (LSD). The analysis showed that TB remained significantly elevated in groups II, III, and IV as compared to controls (p < 0.05). ALP did not have any discriminatory power among the four groups tested. ALT and AST were good discriminators only between the control groups and groups II and III. TP, ALB, and A/G ratio were decreased significantly in groups III and IV as compared to controls. Group III and IV were almost indistinguishable using these biochemical parameters except for AFP, which was found to be elevated only in group IV. The accuracy of classification into different liver patient groups using random Forest and CART was 94% and 95% respectively. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Acute hepatitis (group II) shows a higher level of AST, ALT and ALP compared to chronic hepatitis (group III) and hepatocellular carcinoma (group IV). Two machine learning algorithms also predicted and supported the same biochemical results by correctly classifying liver disease patients. We also recommend that the AFP test can be performed if hepatocellular carcinoma is suspected.展开更多
文摘<b><span style="font-family:Verdana;">Background: </span></b><span style="font-family:""><span style="font-family:Verdana;">The liver function tests (LFTs) remain one of the most commonly employed clinical measures for the diagnosis of hepatobiliary disease. LFTs sometimes referred to as hepatic panel help to determine the health of liver, monitor the progression of a disease and measure the severity of a disease particularly scarring or cirrhosis of the liver. </span><b><span style="font-family:Verdana;">Aims: </span></b><span style="font-family:Verdana;">In this study, we present a new approach to evaluate the natural progression of liver disease through the assessment of eight biochemical </span><span style="font-family:Verdana;">parameters: serum total bilirubin (TB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), Alkaline phosphatase (ALP), total protein (TP), albumin (ALB), albumin/globulin (A/G) ratio, and alpha-fetoprotein (AFP) as well as two ma</span><span style="font-family:Verdana;">chine learning (ML) tools—Random Forest and CART to substantive the outcome. </span><b><span style="font-family:Verdana;">Methods: </span></b><span style="font-family:Verdana;">The study was carried out in a total of 100 subjects which included healthy controls (group I-25 patients), patients with acute hepatitis (group II-25 patients), chronic hepatitis (group III-25 patients) and hepatocellular carcinoma (group IV-25 patients) applying both biochemical and Machine Learning methods. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">Of the eight parameters tested, all except ALP (p = 0.426), showed an overall discriminatory ability as judged by one-factor analysis of variance (p < 0.0001). We also assessed the differences among group means by least significance difference (LSD). The analysis showed that TB remained significantly elevated in groups II, III, and IV as compared to controls (p < 0.05). ALP did not have any discriminatory power among the four groups tested. ALT and AST were good discriminators only between the control groups and groups II and III. TP, ALB, and A/G ratio were decreased significantly in groups III and IV as compared to controls. Group III and IV were almost indistinguishable using these biochemical parameters except for AFP, which was found to be elevated only in group IV. The accuracy of classification into different liver patient groups using random Forest and CART was 94% and 95% respectively. </span><b><span style="font-family:Verdana;">Conclusion: </span></b><span style="font-family:Verdana;">Acute hepatitis (group II) shows a higher level of AST, ALT and ALP compared to chronic hepatitis (group III) and hepatocellular carcinoma (group IV). Two machine learning algorithms also predicted and supported the same biochemical results by correctly classifying liver disease patients. We also recommend that the AFP test can be performed if hepatocellular carcinoma is suspected.
